Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Noninterventional Follow-Up Study of Children Aged 23 to 25 Months, Born to Mothers Who Received Hydroxyprogesterone Caproate Injection, 250 mg/mL, or Vehicle for Prevention of Preterm Birth

Next Previous
Search
Trial Profile

A Prospective, Noninterventional Follow-Up Study of Children Aged 23 to 25 Months, Born to Mothers Who Received Hydroxyprogesterone Caproate Injection, 250 mg/mL, or Vehicle for Prevention of Preterm Birth

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hydroxyprogesterone (Primary)
  • Indications Preterm birth
  • Focus Adverse reactions
  • Sponsors AMAG Pharmaceuticals; Hologic; Lumara Health

Most Recent Events

  • 17 May 2022 Status changed from recruiting to completed.
  • 16 Jul 2020 Planned End Date changed from 1 Oct 2020 to 1 Dec 2020.
  • 16 Jul 2020 Planned primary completion date changed from 1 Aug 2020 to 1 Nov 2020.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top